Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to 0.7.

  • Neurocrine Biosciences' Equity Ratio rose 85.96% to 0.7 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.7, marking a year-over-year increase of 85.96%. This contributed to the annual value of 0.7 for FY2025, which is 85.96% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' Equity Ratio stood at 0.7, which was up 85.96% from 0.7 recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Equity Ratio registered a high of 0.77 during Q3 2024, and its lowest value of 0.65 during Q1 2021.
  • For the 4-year period, Neurocrine Biosciences' Equity Ratio averaged around 0.7, with its median value being 0.7 (2024).
  • Per our database at Business Quant, Neurocrine Biosciences' Equity Ratio skyrocketed by 2698.09% in 2021 and then crashed by 876.64% in 2025.
  • Neurocrine Biosciences' Equity Ratio (Quarter) stood at 0.67 in 2021, then grew by 2.88% to 0.69 in 2023, then rose by 1.45% to 0.7 in 2024, then increased by 0.86% to 0.7 in 2025.
  • Its Equity Ratio was 0.7 in Q4 2025, compared to 0.7 in Q3 2025 and 0.69 in Q2 2025.